 | • レポートコード：MRC2Q12-19272 • 出版社/出版日：QYResearch / 2022年12月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、117ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥710,500 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,421,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、次世代抗体医薬品のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 次世代抗体医薬品のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 次世代抗体医薬品の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 次世代抗体医薬品のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの次世代抗体医薬品の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の次世代抗体医薬品の売上および2028年までの予測に焦点を当てています。 次世代抗体医薬品のグローバル主要企業には、Roche、Amgen、Janssen、Sanofi、Pfizer、Johnson & Johnson、AstraZeneca、AbbVie、Lindis Biotech、MacroGenics, Inc、Genmab、Alphamab Oncology、Akeso、Innovent Biologics、Yzy Medical Science & Technologyなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 次世代抗体医薬品市場は、タイプとアプリケーションによって区分されます。世界の次世代抗体医薬品市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 フラグメントベース、IgGベース 【アプリケーション別セグメント】 がん、血友病、その他疾患 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 次世代抗体医薬品製品概要 - タイプ別市場（フラグメントベース、IgGベース） - アプリケーション別市場（がん、血友病、その他疾患） - 調査の目的 ・エグゼクティブサマリー - 世界の次世代抗体医薬品販売量予測2017-2028 - 世界の次世代抗体医薬品売上予測2017-2028 - 次世代抗体医薬品の地域別販売量 - 次世代抗体医薬品の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別次世代抗体医薬品販売量 - 主要メーカー別次世代抗体医薬品売上 - 主要メーカー別次世代抗体医薬品価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（フラグメントベース、IgGベース） - 次世代抗体医薬品のタイプ別販売量 - 次世代抗体医薬品のタイプ別売上 - 次世代抗体医薬品のタイプ別価格 ・アプリケーション別市場規模（がん、血友病、その他疾患） - 次世代抗体医薬品のアプリケーション別販売量 - 次世代抗体医薬品のアプリケーション別売上 - 次世代抗体医薬品のアプリケーション別価格 ・北米市場 - 北米の次世代抗体医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の次世代抗体医薬品市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの次世代抗体医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の次世代抗体医薬品市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の次世代抗体医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の次世代抗体医薬品市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の次世代抗体医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の次世代抗体医薬品市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの次世代抗体医薬品市場規模（タイプ別、アプリケーション別） - 主要国別の次世代抗体医薬品市場規模（トルコ、サウジアラビア） ・企業情報 Roche、Amgen、Janssen、Sanofi、Pfizer、Johnson & Johnson、AstraZeneca、AbbVie、Lindis Biotech、MacroGenics, Inc、Genmab、Alphamab Oncology、Akeso、Innovent Biologics、Yzy Medical Science & Technology ・産業チェーン及び販売チャネル分析 - 次世代抗体医薬品の産業チェーン分析 - 次世代抗体医薬品の原材料 - 次世代抗体医薬品の生産プロセス - 次世代抗体医薬品の販売及びマーケティング - 次世代抗体医薬品の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 次世代抗体医薬品の産業動向 - 次世代抗体医薬品のマーケットドライバー - 次世代抗体医薬品の課題 - 次世代抗体医薬品の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Next-Generation Antibody Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Next-Generation Antibody Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Next-Generation Antibody Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Next-Generation Antibody Drug include Roche, Amgen, Janssen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie and Lindis Biotech, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Next-Generation Antibody Drug manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Next-Generation Antibody Drug market. Further, it explains the major drivers and regional dynamics of the global Next-Generation Antibody Drug market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Roche
Amgen
Janssen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Oncology
Akeso
Innovent Biologics
Yzy Medical Science & Technology
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Next-Generation Antibody Drug Segment by Type
Fragment-Based
IgG-Based
Next-Generation Antibody Drug Segment by Application
Cancer
Hemophilia
Other Diseases
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Next-Generation Antibody Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Next-Generation Antibody Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Next-Generation Antibody Drug, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Next-Generation Antibody Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Next-Generation Antibody Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Next-Generation Antibody Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Next-Generation Antibody Drug sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Roche, Amgen, Janssen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie and Lindis Biotech, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Next-Generation Antibody Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Next-Generation Antibody Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Next-Generation Antibody Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Next-Generation Antibody Drug Product Introduction
1.2 Market by Type
1.2.1 Global Next-Generation Antibody Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Fragment-Based
1.2.3 IgG-Based
1.3 Market by Application
1.3.1 Global Next-Generation Antibody Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Cancer
1.3.3 Hemophilia
1.3.4 Other Diseases
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Next-Generation Antibody Drug Sales Estimates and Forecasts 2017-2028
2.2 Global Next-Generation Antibody Drug Revenue Estimates and Forecasts 2017-2028
2.3 Global Next-Generation Antibody Drug Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Next-Generation Antibody Drug Sales by Region
2.4.1 Global Next-Generation Antibody Drug Sales by Region (2017-2022)
2.4.2 Global Sales Next-Generation Antibody Drug by Region (2023-2028)
2.5 Global Next-Generation Antibody Drug Revenue by Region
2.5.1 Global Next-Generation Antibody Drug Revenue by Region (2017-2022)
2.5.2 Global Next-Generation Antibody Drug Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Next-Generation Antibody Drug Sales by Manufacturers
3.1.1 Global Top Next-Generation Antibody Drug Manufacturers by Sales (2017-2022)
3.1.2 Global Next-Generation Antibody Drug Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Next-Generation Antibody Drug in 2021
3.2 Global Next-Generation Antibody Drug Revenue by Manufacturers
3.2.1 Global Next-Generation Antibody Drug Revenue by Manufacturers (2017-2022)
3.2.2 Global Next-Generation Antibody Drug Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Next-Generation Antibody Drug Revenue in 2021
3.3 Global Next-Generation Antibody Drug Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Next-Generation Antibody Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Next-Generation Antibody Drug Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Next-Generation Antibody Drug Sales by Type
4.1.1 Global Next-Generation Antibody Drug Historical Sales by Type (2017-2022)
4.1.2 Global Next-Generation Antibody Drug Forecasted Sales by Type (2023-2028)
4.1.3 Global Next-Generation Antibody Drug Sales Market Share by Type (2017-2028)
4.2 Global Next-Generation Antibody Drug Revenue by Type
4.2.1 Global Next-Generation Antibody Drug Historical Revenue by Type (2017-2022)
4.2.2 Global Next-Generation Antibody Drug Forecasted Revenue by Type (2023-2028)
4.2.3 Global Next-Generation Antibody Drug Revenue Market Share by Type (2017-2028)
4.3 Global Next-Generation Antibody Drug Price by Type
4.3.1 Global Next-Generation Antibody Drug Price by Type (2017-2022)
4.3.2 Global Next-Generation Antibody Drug Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Next-Generation Antibody Drug Sales by Application
5.1.1 Global Next-Generation Antibody Drug Historical Sales by Application (2017-2022)
5.1.2 Global Next-Generation Antibody Drug Forecasted Sales by Application (2023-2028)
5.1.3 Global Next-Generation Antibody Drug Sales Market Share by Application (2017-2028)
5.2 Global Next-Generation Antibody Drug Revenue by Application
5.2.1 Global Next-Generation Antibody Drug Historical Revenue by Application (2017-2022)
5.2.2 Global Next-Generation Antibody Drug Forecasted Revenue by Application (2023-2028)
5.2.3 Global Next-Generation Antibody Drug Revenue Market Share by Application (2017-2028)
5.3 Global Next-Generation Antibody Drug Price by Application
5.3.1 Global Next-Generation Antibody Drug Price by Application (2017-2022)
5.3.2 Global Next-Generation Antibody Drug Price Forecast by Application (2023-2028)
6 North America
6.1 North America Next-Generation Antibody Drug Market Size by Type
6.1.1 North America Next-Generation Antibody Drug Sales by Type (2017-2028)
6.1.2 North America Next-Generation Antibody Drug Revenue by Type (2017-2028)
6.2 North America Next-Generation Antibody Drug Market Size by Application
6.2.1 North America Next-Generation Antibody Drug Sales by Application (2017-2028)
6.2.2 North America Next-Generation Antibody Drug Revenue by Application (2017-2028)
6.3 North America Next-Generation Antibody Drug Market Size by Country
6.3.1 North America Next-Generation Antibody Drug Sales by Country (2017-2028)
6.3.2 North America Next-Generation Antibody Drug Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Next-Generation Antibody Drug Market Size by Type
7.1.1 Europe Next-Generation Antibody Drug Sales by Type (2017-2028)
7.1.2 Europe Next-Generation Antibody Drug Revenue by Type (2017-2028)
7.2 Europe Next-Generation Antibody Drug Market Size by Application
7.2.1 Europe Next-Generation Antibody Drug Sales by Application (2017-2028)
7.2.2 Europe Next-Generation Antibody Drug Revenue by Application (2017-2028)
7.3 Europe Next-Generation Antibody Drug Market Size by Country
7.3.1 Europe Next-Generation Antibody Drug Sales by Country (2017-2028)
7.3.2 Europe Next-Generation Antibody Drug Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Next-Generation Antibody Drug Market Size by Type
8.1.1 Asia Pacific Next-Generation Antibody Drug Sales by Type (2017-2028)
8.1.2 Asia Pacific Next-Generation Antibody Drug Revenue by Type (2017-2028)
8.2 Asia Pacific Next-Generation Antibody Drug Market Size by Application
8.2.1 Asia Pacific Next-Generation Antibody Drug Sales by Application (2017-2028)
8.2.2 Asia Pacific Next-Generation Antibody Drug Revenue by Application (2017-2028)
8.3 Asia Pacific Next-Generation Antibody Drug Market Size by Region
8.3.1 Asia Pacific Next-Generation Antibody Drug Sales by Region (2017-2028)
8.3.2 Asia Pacific Next-Generation Antibody Drug Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Next-Generation Antibody Drug Market Size by Type
9.1.1 Latin America Next-Generation Antibody Drug Sales by Type (2017-2028)
9.1.2 Latin America Next-Generation Antibody Drug Revenue by Type (2017-2028)
9.2 Latin America Next-Generation Antibody Drug Market Size by Application
9.2.1 Latin America Next-Generation Antibody Drug Sales by Application (2017-2028)
9.2.2 Latin America Next-Generation Antibody Drug Revenue by Application (2017-2028)
9.3 Latin America Next-Generation Antibody Drug Market Size by Country
9.3.1 Latin America Next-Generation Antibody Drug Sales by Country (2017-2028)
9.3.2 Latin America Next-Generation Antibody Drug Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Next-Generation Antibody Drug Market Size by Type
10.1.1 Middle East and Africa Next-Generation Antibody Drug Sales by Type (2017-2028)
10.1.2 Middle East and Africa Next-Generation Antibody Drug Revenue by Type (2017-2028)
10.2 Middle East and Africa Next-Generation Antibody Drug Market Size by Application
10.2.1 Middle East and Africa Next-Generation Antibody Drug Sales by Application (2017-2028)
10.2.2 Middle East and Africa Next-Generation Antibody Drug Revenue by Application (2017-2028)
10.3 Middle East and Africa Next-Generation Antibody Drug Market Size by Country
10.3.1 Middle East and Africa Next-Generation Antibody Drug Sales by Country (2017-2028)
10.3.2 Middle East and Africa Next-Generation Antibody Drug Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Overview
11.1.3 Roche Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Roche Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Roche Recent Developments
11.2 Amgen
11.2.1 Amgen Corporation Information
11.2.2 Amgen Overview
11.2.3 Amgen Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Amgen Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Amgen Recent Developments
11.3 Janssen
11.3.1 Janssen Corporation Information
11.3.2 Janssen Overview
11.3.3 Janssen Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Janssen Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Janssen Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Overview
11.4.3 Sanofi Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Sanofi Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Sanofi Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Overview
11.5.3 Pfizer Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Pfizer Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Pfizer Recent Developments
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Corporation Information
11.6.2 Johnson & Johnson Overview
11.6.3 Johnson & Johnson Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Johnson & Johnson Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Johnson & Johnson Recent Developments
11.7 AstraZeneca
11.7.1 AstraZeneca Corporation Information
11.7.2 AstraZeneca Overview
11.7.3 AstraZeneca Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 AstraZeneca Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 AstraZeneca Recent Developments
11.8 AbbVie
11.8.1 AbbVie Corporation Information
11.8.2 AbbVie Overview
11.8.3 AbbVie Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 AbbVie Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 AbbVie Recent Developments
11.9 Lindis Biotech
11.9.1 Lindis Biotech Corporation Information
11.9.2 Lindis Biotech Overview
11.9.3 Lindis Biotech Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Lindis Biotech Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Lindis Biotech Recent Developments
11.10 MacroGenics, Inc
11.10.1 MacroGenics, Inc Corporation Information
11.10.2 MacroGenics, Inc Overview
11.10.3 MacroGenics, Inc Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 MacroGenics, Inc Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 MacroGenics, Inc Recent Developments
11.11 Genmab
11.11.1 Genmab Corporation Information
11.11.2 Genmab Overview
11.11.3 Genmab Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Genmab Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Genmab Recent Developments
11.12 Alphamab Oncology
11.12.1 Alphamab Oncology Corporation Information
11.12.2 Alphamab Oncology Overview
11.12.3 Alphamab Oncology Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Alphamab Oncology Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Alphamab Oncology Recent Developments
11.13 Akeso
11.13.1 Akeso Corporation Information
11.13.2 Akeso Overview
11.13.3 Akeso Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Akeso Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Akeso Recent Developments
11.14 Innovent Biologics
11.14.1 Innovent Biologics Corporation Information
11.14.2 Innovent Biologics Overview
11.14.3 Innovent Biologics Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Innovent Biologics Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Innovent Biologics Recent Developments
11.15 Yzy Medical Science & Technology
11.15.1 Yzy Medical Science & Technology Corporation Information
11.15.2 Yzy Medical Science & Technology Overview
11.15.3 Yzy Medical Science & Technology Next-Generation Antibody Drug Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Yzy Medical Science & Technology Next-Generation Antibody Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Yzy Medical Science & Technology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Next-Generation Antibody Drug Industry Chain Analysis
12.2 Next-Generation Antibody Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Next-Generation Antibody Drug Production Mode & Process
12.4 Next-Generation Antibody Drug Sales and Marketing
12.4.1 Next-Generation Antibody Drug Sales Channels
12.4.2 Next-Generation Antibody Drug Distributors
12.5 Next-Generation Antibody Drug Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Next-Generation Antibody Drug Industry Trends
13.2 Next-Generation Antibody Drug Market Drivers
13.3 Next-Generation Antibody Drug Market Challenges
13.4 Next-Generation Antibody Drug Market Restraints
14 Key Findings in The Global Next-Generation Antibody Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
| 【次世代抗体医薬品について】 次世代抗体医薬品は、従来の抗体医薬品の概念を超えて、より効果的で特異的な治療を実現するための新しいアプローチを提供する薬剤群を指します。これらの医薬品は、特にがん治療や自己免疫疾患、感染症などにおいて、大きな可能性を秘めています。 次世代抗体医薬品の定義としては、標的分子への結合特異性を高めたり、毒性を低減させたりするために技術的改善が施された抗体です。これには様々な分子工学手法や新しいプラットフォーム技術が活用され、従来の一対一の標的アプローチから、多様なメカニズムを通じた治療効果が期待されています。 次世代抗体医薬品の特徴には、以下のような点が挙げられます。まず、より高い親和性を持つ抗体が設計されており、特定の病変細胞に対して選択的に結合することで、副作用を低減できます。次に、抗体が自身の機能を補完する形式で他の薬剤と併用されることにより、治療効果が増強される点も特徴として挙げられます。また、一部の次世代抗体医薬品は、抗体と薬剤が結合した薬物複合体（ADC: Antibody-Drug Conjugates）として開発されており、特異的に標的細胞内に薬物を届ける能力を持っています。 次世代抗体医薬品の種類としては、さまざまな形態があります。バイオシミラーや完全人抗体、抗体のエンジニアリング技術を用いた単クローン抗体、二重特異性抗体（bispecific antibodies）などが挙げられます。特に二重特異性抗体は、二つの異なる抗原に結合する能力を持ち、複数の病理機序に同時に作用できるため、がん治療や免疫療法の分野で注目を集めています。 用途に関しては、次世代抗体医薬品は、がんを含む腫瘍治療や、自己免疫疾患、血液疾患、さらにはウイルス感染症に対する治療など多岐にわたります。例えば、がん細胞の特定のマーカーに対する高い親和性を持つ抗体が、抗がん剤を直接がん細胞に届けることができれば、副作用を軽減し、治療効果を向上させることができます。また、自己免疫疾患においては、過剰な免疫応答を抑制するために特定の免疫細胞に作用する抗体が有効です。 次世代抗体医薬品の開発には、様々な関連技術が重要な役割を果たしています。例えば、抗体のデザインには、フィリックスダーウやヒト化技術、さらにはインシリコモデリングなどが活用されます。これにより、抗体の特異性や親和性を高めることが可能になります。また、高度なスクリーニング技術を用いて、多数の抗体候補から選抜するプロセスも改善されており、より迅速かつ効率的な開発が行えるようになっています。 さらに、次世代抗体医薬品の開発には、製造プロセスの技術革新も不可欠です。糖鎖修飾や工程のスケールアップ、コスト削減技術は、バイオ医薬品の商業化にも大きな影響をもたらします。最近では、セルフ・アセンブリ技術や微生物発酵プロセスの活用が進んでおり、より効率的に抗体を生産することが可能になっています。 次世代抗体医薬品は、今後の医療分野においてさらに重要な位置を占めることでしょう。その治療対象が広がり、より個別化された治療法が提供されることで、患者のQOL（生活の質）が向上することが期待されています。また、新たなバイオ技術の進展により、より迅速かつ効率的に抗体候補がラインアップされることが可能になり、革新的な治療法が続々と市場に登場することが予想されます。 総じて、次世代抗体医薬品は、その特異性や効率性、さらには多様な用途により、医療の現場での役割が増していくと考えられます。技術革新が絶えず進む中、次世代抗体医薬品の概念は、まさに未来の医療の中核をなすものとなるでしょう。今後の研究開発の進展に期待が寄せられています。 |